Syndax Pharmaceuticals Inc: STATE STREET CORP discloses a stake of more than 5% (Schedule 13G)
Not investment advice. Muhabbit scores how much a story may matter, not which way to trade.
State Street Corp disclosed a stake exceeding 5% in Syndax Pharmaceuticals Inc via a Schedule 13G filing with the SEC (accession 0000093751-26-000728). The filing signals that the institutional investor has crossed the key 5% beneficial ownership threshold, making it a reportable major holder in the clinical-stage biopharmaceutical company. The disclosure does not specify the exact number of shares or the percentage held beyond the 5% minimum. Investors will watch for further 13G amendments or 13D filings that could clarify whether the position is passive or activist in nature.
Muhabbit's AI wrote this summary in its own words from SEC EDGAR SCHEDULE 13G's report. It can get details wrong, so check the source.
Named in this story
Syndax Pharmaceuticals Inc, State Street Corp